Purolite celebrates expansion of innovative bioprocessing facility in Wales
.png)
L-R: Hayley Crowe, Deputy Mayor Wendy Lewis, Chris Major, His Majesty's Lord-Lieutenant of Mid Glamorgan Peter Vaughan, Gergely Sved
Purolite, an Ecolab company, marked the opening of a new Customer Experience Centre featuring hands-on interactive and educational displays, showcasing the company’s expanded bioprocessing solutions.
Ecolab company Purolite held its ribbon-cutting ceremony on October 13 in celebration of their manufacturing expansion, which will see production capacity triple for the company’s bioprocessing resin production to meet global demands. In an interview with Chris Major, General Manager of the Bioprocessing division, Purolite’s expanded features will also bring attention to its commitment to the environmental impact of manufacturers.
L-R: Chris Major, Hayley Crowe, His Majesty's Lord-Lieutenant of Mid Glamorgan Peter Vaughan
The expansion includes a newly opened Customer Experience Centre featuring hands-on interactive and touch-screen educational displays showcasing Purolite’s bioprocessing solutions. As part of a multimillion-dollar global investment from Ecolab, increased office space, training areas, and conference room facilities will also be on offer.
Major stated: “It creates a space where our team can be really creative. When you’ve got some of the brightest minds in the industry, you want to have a nice place for them to work – you want to have a place where they feel inspired and where they can think about the next-generation products that are going to help impact the next generation of therapeutics, that’s what the innovation centre does. It creates an environment for our people to be free-thinking and innovative.”
Major emphasized Purolite’s continued commitment to bringing their customers sustainable processes and an ethical environment for their manufacturing needs. As a modular-built facility with 27 Portacabins, each cabin boasts the usage of second-use recycled steel. Groundwater heat pumps utilise thermal energy, which can be converted to use as renewable energy throughout the facility. Solar panels run the facility at close to net-zero energy. However Major noted that such facility features are only a small part of Purolite’s commitment to sustainability.
L-R: Hayley Crowe, Chris Major, Gergely Sved
“The big advantage that we have is the technology we have developed. For the last 50 years, there’s really been one method of manufacturing the type of technology that we do, and it has remained virtually unchanged since the 1950s. Over the last five to seven years, we’ve worked to revolutionise this type of a manufacturing method to something we’ve patented called ‘jetting method’. Jetting technology allows us to precisely control size to make uniform beads... By the way that we’ve designed and implemented this manufacturing technology, we’ve been able to substantially reduce the amount of water (compared to the traditional manufacturing method).” In addition to reducing water usage and wastage, Major also stated that carbon dioxide emissions were significantly reduced with the patented jetting method, as well as almost eliminating harmful solvents. With sustainable manufacturing methods, Major highlights that Purolite not only reduces their own environmental impact but also that of their customers who choose to partner with them.
The expanded facility in Wales runs in parallel to construction at Purolite’s facility in the United States, giving Purolite a dual-continent capability to make innovative therapeutics around the world accessible. Major emphasized that a pillar of Purolite’s ethos is not only to develop and manufacture exciting new technologies in support of biopharmaceuticals, but to also make healthcare an accessible right across the globe.
Major concluded with a highlight of some of Purolite’s business achievements, including a series of global awards and recognitions. Purolite UK was awarded the Queen's Award for Enterprise in 2022, given by His Majesty’s Lord Lieutenant of Mid Glamorgan. With a wider global footprint, Purolite’s headcount has almost doubled, something Major anticipates will only increase in the coming years. The Wales Business Award for Most Innovative Company was also presented to Purolite, further demonstrating Purolite’s commitment and production of cutting-edge technology.
Read more about Purolite’s expansion here.

Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance